JW Therapeutics Receives the NMPA’s Approval for Carteyva (relmacabtagene autoleucel) sNDA to Treat Relapsed or Refractory Follicular Lymphoma
- The approval was based on the 6mos. results from cohort B of (RELIANCE) study evaluating Carteyva in adult patients with r/r B cell non-Hodgkin lymphoma in China
- The results showed a very high rate of durable disease response; ORR (100%), CRR (85.19%) @3mos. while ORR (92.58%), CRR (77.78%) @6mos., controllable CAR-T associated toxicities in patients with r/r FL and safety profile was manageable
- Relmacabtagene autoleucel is an autologous anti-CD19 CAR-T cell immunotherapy product, developed by JW Therapeutics. The therapy was approved in China for 2 indications i.e., r/r large B-cell lymphoma & FL, and has been included in the national significant new drug development program, granted priority review & BTD
Ref: Businesswire | Image: JW Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.